XENE - What's Going On With Neurology-Focused Xenon Pharmaceuticals' Stock Today? | Benzinga
Xenon Pharmaceuticals Inc (NASDAQ: XENE) reported topline results from the Phase 2 proof-of-concept X-NOVA trial, which evaluated the clinical efficacy, safety, and tolerability of 10 mg and 20 mg of XEN1101 in 168 patients with moderate to severe major depressive disorder (MDD).
- The study's primary endpoint was a change in the Montgomery-Åsberg Depression Rating Scale (MADRS) at week 6. The mean reduction was 13.90 in the placebo group, 15.61 in the XEN1101 10 mg group, and 16.94 in ...